Literature DB >> 14726455

Infection control in cystic fibrosis.

Lisa Saiman1, Jane Siegel.   

Abstract

Over the past 20 years there has been a greater interest in infection control in cystic fibrosis (CF) as patient-to-patient transmission of pathogens has been increasingly demonstrated in this unique patient population. The CF Foundation sponsored a consensus conference to craft recommendations for infection control practices for CF care providers. This review provides a summary of the literature addressing infection control in CF. Burkholderia cepacia complex, Pseudomonas aeruginosa, and Staphylococcus aureus have all been shown to spread between patients with CF. Standard precautions, transmission-based precautions including contact and droplet precautions, appropriate hand hygiene for health care workers, patients, and their families, and care of respiratory tract equipment to prevent the transmission of infectious agents serve as the foundations of infection control and prevent the acquisition of potential pathogens by patients with CF. The respiratory secretions of all CF patients potentially harbor clinically and epidemiologically important microorganisms, even if they have not yet been detected in cultures from the respiratory tract. CF patients should be educated to contain their secretions and maintain a distance of >3 ft from other CF patients to avoid the transmission of potential pathogens, even if culture results are unavailable or negative. To prevent the acquisition of pathogens from respiratory therapy equipment used in health care settings as well as in the home, such equipment should be cleaned and disinfected. It will be critical to measure the dissemination, implementation, and potential impact of these guidelines to monitor changes in practice and reduction in infections.

Entities:  

Mesh:

Year:  2004        PMID: 14726455      PMCID: PMC321464          DOI: 10.1128/CMR.17.1.57-71.2004

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  185 in total

Review 1.  Behavioral interventions to improve infection control practices.

Authors:  E K Kretzer; E L Larson
Journal:  Am J Infect Control       Date:  1998-06       Impact factor: 2.918

2.  Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee.

Authors:  J S Garner
Journal:  Infect Control Hosp Epidemiol       Date:  1996-01       Impact factor: 3.254

3.  An organizational climate intervention associated with increased handwashing and decreased nosocomial infections.

Authors:  E L Larson; E Early; P Cloonan; S Sugrue; M Parides
Journal:  Behav Med       Date:  2000       Impact factor: 3.104

4.  Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients.

Authors:  G Fluge; B Ojeniyi; N Høiby; A Digranes; O Ciofu; E Hunstad; O C Haanaes; O T Storrøsten
Journal:  Clin Microbiol Infect       Date:  2001-05       Impact factor: 8.067

5.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

6.  Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships.

Authors:  C Schlichting; C Branger; J M Fournier; W Witte; A Boutonnier; C Wolz; P Goullet; G Döring
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

7.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

Review 8.  Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Am J Infect Control       Date:  2003-05       Impact factor: 2.918

9.  Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment.

Authors:  J E Mortensen; M C Fisher; J J LiPuma
Journal:  Infect Control Hosp Epidemiol       Date:  1995-01       Impact factor: 3.254

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  92 in total

1.  A new highly discriminatory multiplex capillary-based MLVA assay as a tool for the epidemiological survey of Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  D Sobral; P Mariani-Kurkdjian; E Bingen; H Vu-Thien; K Hormigos; B Lebeau; F Loisy-Hamon; A Munck; G Vergnaud; C Pourcel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-11       Impact factor: 3.267

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  The Burkholderia cenocepacia LysR-type transcriptional regulator ShvR influences expression of quorum-sensing, protease, type II secretion, and afc genes.

Authors:  Eoin P O'Grady; David T Nguyen; Laure Weisskopf; Leo Eberl; Pamela A Sokol
Journal:  J Bacteriol       Date:  2010-10-22       Impact factor: 3.490

4.  Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Kathleen M Thickett; David Honeybourne; Martin C J Maiden; John R Govan; David P Speert; John J Lipuma; Peter Vandamme; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex.

Authors:  Karlene H Lynch; Jonathan J Dennis
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

6.  Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex.

Authors:  Kimberley D Seed; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.

Authors:  Mark W Musch; Yunwei Wang; Erika C Claud; Eugene B Chang
Journal:  Dig Dis Sci       Date:  2013-01-18       Impact factor: 3.199

8.  Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis.

Authors:  Kay A Ramsay; Claire A Butler; Stuart Paynter; Robert S Ware; Timothy J Kidd; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

9.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

10.  Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives.

Authors:  Kristen K Marciel; Lisa Saiman; Lynne M Quittell; Kevin Dawkins; Alexandra L Quittner
Journal:  Pediatr Pulmonol       Date:  2010-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.